This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Endocrine/metabolic disease				
Diabetes	Sirtuin 1 (SIRT1)	<p><i>In vitro</i> and mouse studies suggest inhibiting SIRT1 specifically in neurons could help treat type 2 diabetes. Prior studies have suggested that peripheral SIRT1 activation could help treat the disease, but results have been inconsistent. In mice, neuron-specific knockout of <i>Sirt1</i> increased insulin sensitivity and glucose tolerance compared with no knockout. Next steps could include identifying strategies to prevent peripherally acting SIRT1 activators from accessing the CNS.</p> <p>Elixir Pharmaceuticals Inc.'s EX-527, an oral SIRT1 inhibitor, is in Phase II testing to treat Huntington's disease (HD).</p> <p>GlaxoSmithKline plc's GSK2245840 SIRT1 activator is in Phase II testing to treat psoriasis. The compound completed Phase I/II trials for type 2 diabetes, but the pharma said it is no longer pursuing that indication with the compound.</p> <p>Ildong Pharmaceutical Co. Ltd.'s SIRT1 activator, ID2244, is in preclinical development to treat metabolic syndrome.</p> <p>SciBX 6(12); doi:10.1038/scibx.2013.288 Published online March 28, 2013</p>	Findings unpatented; available for partnerships	<p>Lu, M. <i>et al. J. Biol. Chem.</i>; published online March 1, 2013; doi:10.1074/jbc.M112.443606 Contact: Jerrold M. Olefsky, University of California, San Diego, La Jolla, Calif. e-mail: jolefsky@ucsd.edu</p>